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Abstract
Multi-drug therapy is the standard-of-care treatment for tuberculosis. Despite this, virtually all studies of the
pharmacodynamics (PD) of mycobacterial drugs employed for the design of treatment protocols are restricted to single
agents. In this report, mathematical models and in vitro experiments with Mycobacterium marinum and five
antimycobacterial drugs are used to quantitatively evaluate the pharmaco-, population and evolutionary dynamics of
two-drug antimicrobial chemotherapy regimes. Time kill experiments with single and pairs of antibiotics are used to
estimate the parameters and evaluate the fit of Hill-function-based PD models. While Hill functions provide excellent fits for
the PD of each single antibiotic studied, rifampin, amikacin, clarithromycin, streptomycin and moxifloxacin, two-drug Hill
functions with a unique interaction parameter cannot account for the PD of any of the 10 pairs of these drugs. If we assume
two antibiotic-concentration dependent functions for the interaction parameter, one for sub-MIC and one for supra-MIC
drug concentrations, the modified biphasic Hill function provides a reasonably good fit for the PD of all 10 pairs of
antibiotics studied. Monte Carlo simulations of antibiotic treatment based on the experimentally-determined PD functions
are used to evaluate the potential microbiological efficacy (rate of clearance) and evolutionary consequences (likelihood of
generating multi-drug resistance) of these different drug combinations as well as their sensitivity to different forms of non-
adherence to therapy. These two-drug treatment simulations predict varying outcomes for the different pairs of antibiotics
with respect to the aforementioned measures of efficacy. In summary, Hill functions with biphasic drug-drug interaction
terms provide accurate analogs for the PD of pairs of antibiotics and M. marinum. The models, experimental protocols and
computer simulations used in this study can be applied to evaluate the potential microbiological and evolutionary efficacy
of two-drug therapy for any bactericidal antibiotics and bacteria that can be cultured in vitro.
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Introduction
The concurrent use of multiple drugs, which is one of the
mainstays of chemotherapy, is useful and in some cases necessary
for the successful treatment of diseases such as tuberculosis (TB),
HIV/AIDS, malaria and various cancers. Shortly after antimyco-
bacterial agents became available for treating TB, it was
recognized that single drug therapy almost invariably led to
treatment failure due to the ascent of resistance, but that this could
be mitigated by the use of multiple drugs with different modes of
action [1–4]. In its current form, standard tuberculosis treatment
consists of a two-month combinatorial course of rifampin,
isoniazid, pyrazinamide and ethambutol, followed by a four-
month continuation phase of isoniazid and rifampin.
Despite the barrage of antibiotics and long term of combination
therapy, Mycobacterium tuberculosis (Mtb) strains that are resistant to
multiple drugs are an increasingly troubling component of the
epidemiological landscape. In 2009, the World Health Organiza-
tion estimated close to half a million cases of multidrug resistant
(MDR) TB (cases in which recovered strains were resistant to the
most potent first-line antibiotics, rifampin and isoniazid) [5]. By
mid-2010, 58 countries had reported at least one case of
extensively drug-resistant (XDR) TB (MDR strains that are
additionally resistant to any fluoroquinolone as well as at least
one of the injectable drugs capreomycin, kanamycin and
amikacin) [5]. The important issue is thus: how can the term of
tuberculosis chemotherapy and the likelihood of treatment failure
due to the evolution of resistance during the course of therapy be
reduced?
One approach to improving the efficacy of single drug therapy
has been to design treatment regimes based on in vivo data of the
changes in the concentration of the antibiotic, pharmacokinetics
(PK), and in vitro data on the relationship between the
concentration of the drug and the rate of growth/death of the
bacteria, pharmacodynamics (PD) [6–9]. This PK/PD approach
to the rational design of antibiotic treatment regimes has been
employed for tuberculosis but almost exclusively for single
antibiotics [10–19]. To extend this approach to the multi-drug
treatment regimes clearly needed to prevent acquired resistance, it
is necessary to concurrently account for the PD of the different
drugs, and most critically, how they interact [20–22].
Drug interactions are generally classified as antagonistic,
synergistic or additive. In the case of bactericidal antibiotics,
additive interactions are usually described in one of two ways,
‘Bliss Independence’ and ‘Loewe Additivity’. Bliss Independence
asserts that each drug in a combination exerts its killing action
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two drugs, A and B, and at particular concentrations they kill fa
and fb (0,fa,fb,1) fractions of a bacterial population in an hour, at
the end of the hour the viable cell density would be reduced to (1-
fa)(1-fb) of its initial level. For Loewe additivity, the fraction of
surviving cells with both drugs would be 1-fa-fb, the constraint
being that fa+fb,1 [24]. Antagonism and synergism can then be
defined relative to one of these descriptions of additivity: drugs
interact antagonistically if their combined cidal activity is less than
would be predicted for an additive drug combination, and
synergistically if the cidal activity is more.
Unfortunately, these definitions cannot be readily translated
into the PD of two drugs as they do not account for how the rate or
extent of killing would vary with the concentrations of the drug.
To address this, Greco and colleagues proposed a seminal Emax-
based two-drug pharmacodynamic function which assumes that a
single parameter can account for the interaction between both
drugs [25,26]. If the value of this parameter is zero, then the drugs
are additive, with a negative value indicating antagonism and a
positive value indicating synergy. Although this and other Emax-
based models have been used to characterize the nature of the
interactions between different kinds of drugs, including antimi-
crobials [27–33], there has been limited quantitative consideration
of how two-drug PD models apply to the design and evaluation of
antibiotic treatment regimes for bacteria, particularly those, like
tuberculosis, where multiple drug therapy is essential [27,33].
In this study, we explore the fit of Hill functions (which subsume
Emax models) for the PD of the antimycobacterial antibiotics
rifampin, amikacin, clarithromycin, streptomycin and moxiflox-
acin. We then employ a Hill-function-based variant of the Greco
model to explore the PD of the 10 possible pairs of these drugs. As
our experimental organism, we use Mycobacterium marinum.I n
addition to being safer and more convenient to work with, M.
marinum is a close genetic relative and shares numerous virulence
determinants with Mtb. It also recapitulates key immunopatho-
logical features of human tuberculosis infection in its natural
poikilothermic hosts [34–36].
To explore the potential clinical implications of these theoretical
and in vitro PD studies, we use Monte Carlo simulations of
antibiotic treatment and resistance that incorporate PD functions
that best fit our data. Of particular concern in this analysis are: (i)
the relative rates at which these different drug combinations clear
the simulated infections (their microbiological efficacy) (ii) the
likelihood of resistance to the two drugs evolving during the course
of therapy (their evolutionary efficacy), and (iii) how that efficacy is
affected by different forms of non-adherence to the treatment
regime.
Results
Single drug pharmacodynamics
In Figure 1 we show the fit of the theoretical single-drug
pharmacodynamic function (Equation 1) to the PD data obtained
from experiments with five antimycobacterial agents. These data
were generated by exposing M. marinum to the antibiotics at
different concentrations and estimating net bacterial growth/death
rates (based on the increase or decrease in the density of viable
bacteria) over 72 hours. The analyses of these time-kill data were
restricted to 72 hours in order to ensure that bacteria were
growing and/or being killed exponentially.
For single antibiotics, the Hill function provides a good fit for
the relationship between the concentration of the drug and the
growth/death rate of the bacteria (Figure 1, see R
2 values). This is
also evident in Table 1, where we list the estimates of the Hill
function parameters for each of the drugs. The maximum growth
rates calculated from this function are very close to that estimated
independently (data not shown). Moreover, the estimated zMIC’s
(MIC’s calculated from the Hill functions) and MIC’s determined
by the CLSI [37] recommended broth dilution method are, given
the factor of two limitation of the latter, coincident. The individual
antibiotics exhibited different pharmacodynamic signatures re-
flected in the varying shapes of the PD function (the parameter k)
and the kill rate parameter ymin, which ranged from 20.043 to
20.166 h
21.
Two-drug pharmacodynamics
With the PD function parameter estimates for single antibiotics
in hand, we proceeded to assess the validity of the two-drug
pharmacodynamic function (Equation 3). To accomplish this, we
exposed M. marinum to combinations of antibiotics, each of which
was at some multiple of its respective MIC, and estimated the
growth/death rates of the bacteria over 72 hours. Using the
differential equation (Equation 4), the estimated single-drug Hill
function parameters and different values of a, we compared the
observed growth/death rates to those anticipated from the unique
a model.
In Figure 2 we show the experimentally-observed changes in
bacterial growth/death rates generated by different two-antibiotic
combinations (curves with markers) together with those predicted
from our model for different drug interaction parameters, the a’s
(curves without markers). Our estimates of these growth/death
rates were limited to situations where the density of surviving cells
exceeded 10 CFU per ml. Both the experimental and theoretical
analyses were conducted for all possible two-drug combinations of
the antimycobacterial drugs used in the study.
For all the drug combinations, it is apparent that a single
interaction parameter is insufficient to describe the dynamics over
the entire range of concentrations assessed. While the deviation of
fit from this single a function varies among antibiotic pairs, in all
Author Summary
The goal of this investigation is the development and a
priori evaluation of multi-drug treatment regimes that are
effective in clearing long-term bacterial infections like
tuberculosis, and also minimize the likelihood of multi-
drug resistance arising during therapy. To achieve this end,
we use mathematical models and in vitro experiments with
Mycobacterium marinum (a close relative of M. tuberculosis)
and five different antimycobacterial agents to develop and
validate realistic analogues of the pharmacodynamics of
two-drug chemotherapy. All ten drug pairs examined
exhibited the same general biphasic drug-drug interaction
properties: at low concentrations (subMICs), the two drugs
together were less effective than anticipated from their
independent pharmacodynamics (were antagonistic), but
as their concentrations increased, the interactions between
the antibiotics became relatively more synergistic. Using
computer simulations with these empirically estimated
two-drug pharmacodynamic functions, we evaluated the
relative efficacy of the different antibiotic combinations in
terms of the anticipated rate of clearance of infections and
the likelihood of resistance arising with and without non-
adherence to a treatment regime. The simulations predict
different outcomes for each of the drug combinations. The
models and experimental methods used in this study can
be applied to characterize any combinations of bacteri-
cidal antibiotics and evaluate their potential efficacy.
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greater than that anticipated from the model. The fit with a single
value of a does, however, get somewhat better at higher drug
concentrations.
To get a better idea of the relationship between antibiotic
concentration and a, we used Equation 5 to separately estimate
this interaction parameter for different concentrations of the ten
drug pairs (Figure 3). For all antibiotic combinations, this
interaction became relatively more synergistic with increasing
drug concentration. Interactions at sub-MIC concentrations were
universally antagonistic, but could be mildly antagonistic, additive
or synergistic at supra-MIC concentrations (Figure 3 and Table
S1). In addition, the rate of change in a from one concentration to
the next was much greater at sub-MIC than at supra-MIC
concentrations. Interaction coefficients at the larger concentrations
only changed to a limited extent and appeared to approach
constancy, mirroring the results shown in Figure 2. Although not
providing a precise fit to these data, if we assume a two-phase
interaction function, one for sub- and one for supra-MIC
concentrations and use linear regressions to generate the a
functions for each phase, a reasonable fit obtains (Figure 3 and
Table S1).
Asymmetric antibiotic concentrations
For convenience, but also to make this approach to evaluating
the pharmaco- and population dynamics of two-drug antibiotic
treatment readily applicable, we restricted the above PD
experiments to situations in which both antibiotics were at the
same xMIC concentration. In an effort to explore the robustness of
the two-drug PD observed for these cases of symmetric drug
Figure 1. Fit of the Hill function to time-kill data for single antibiotics. Adjusted R
2 values determined from an F test are shown. (a) Rifampin,
(b) Amikacin, (c) Clarithromycin, (d) Streptomycin, (e) Moxifloxacin.
doi:10.1371/journal.ppat.1002487.g001
Table 1. Single-drug pharmacodynamic function parameter estimates and standard errors.
Drug ymax (h
21) ymin (h
21) k zMIC (mg/L) MIC (mg/L)
Rifampin 0.045360.0018 20.12560.0072 0.92560.17 1.2760.22 0.512
Amikacin 0.045760.0012 20.14560.0019 1.2360.12 0.3860.029 0.5
Clarithromycin 0.048360.00068 20.043460.0013 0.78360.077 1.5860.14 1
Streptomycin 0.046560.0021 20.13460.013 0.50860.11 2.3160.50 2
Moxifloxacin 0.047860.0015 20.16660.0052 0.86360.091 0.46160.055 0.37
doi:10.1371/journal.ppat.1002487.t001
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asymmetric (unequal xMIC concentrations) situations: (i) where
both antibiotics are below their respective MICs, (ii) where one
antibiotic is below its MIC and the other above and (iii) where
both are above their MICs.
When both antibiotics are below the MIC, there is antagonism
similar to that observed for the symmetric case. This can be seen
in Figure S1, where we present the observed growth rates and
those anticipated for situations where there is no interaction
between the drugs, a=0. As would have been anticipated from
the symmetric combination results (Figure 2), at sub MICs the
d r u g st o g e t h e rk i l la tal o w e rr a t et h a ne x p e c t e dw e r et h e r en o
interactions between them i.e. they exhibit antagonism. More-
over, the estimated a’s for the combination of 0.1 and 0.5 xMIC
concentrations of the antibiotics were generally less negative than
those calculated for combinations of 0.1-0.1xMIC but more
negative than those calculated for the 0.5-0.5 xMIC symmetric
cases (Table S2).
Of particular concern in situations where one drug is below the
MIC and the other above is that the substantial antagonism
observed for below-MIC antibiotic concentrations would be
manifest by sub-MIC drugs reducing the efficacy of supra-MIC
antibiotics. The results of our experiments indicate that this is not
the case (Figure S2). When combined with a sub-MIC concen-
tration of a second drug, the rate of kill of the supra-MIC drug is
no less than that when it is alone and in some cases greater.
To explore the effects of asymmetric concentrations for pairs of
above-MIC antibiotics, we compared the observed death rate with
that anticipated for no interaction between the antibiotics. The
results of these experiments suggest that there is either no
interaction between the antibiotic pairs or there is the mild
antagonism or synergy observed for the symmetric drug
concentration experiments (Figure S3).
In sum, the results of these experiments with asymmetric drug
concentrations are consistent with that anticipated from the
symmetric concentration experiments depicted in Figure 3.
Predicted dynamics of treatment
To evaluate how the pharmacodynamics estimated above
would be manifest in a treatment regime, we use a simulation of
the within-host population dynamics of bacteria in a two-drug
therapy regime for tuberculosis. In Figure 4, we present a diagram
of the model used for the analysis (equations for the model can be
found in Protocol S1). In designing this model and in choosing the
dosing parameters, bacterial densities and PD parameters, we tried
to mimic that which would be appropriate for mycobacterial
chemotherapy. The structure of our model is based on that
suggested by D. Mitchison [38]. It assumes two compartments,
one in which the bacteria are actively proliferating and the other
where they are dividing slowly and thereby responding differently
to antibiotics [39,40]. This compartment difference in antibiotic
susceptibility is reflected in the pharmacodynamic Hill functions,
such that the maximum and minimum rates of growth/death are
proportional to the rate of replication in the two compartments.
The idea is that the slowly dividing subpopulation is relatively
refractory to killing by the antibiotics, as would be the case for
latent or persister cells in a tuberculosis infection.
We allow for four states of the bacteria, one that is susceptible to
both drugs, S0 and L0 (S and L for rapidly- and slowly-dividing
populations respectively), S1 and L1 for those resistant to drug 1,
S2 and L2 for cells resistant to drug 2, and S12 and L12 for cells
that are resistant to both drugs. These variables are both the
densities (cells/ml) of bacteria in these states as well as their state
designations. By resistance we are assuming that these bacteria are
totally refractory to the drugs, with MICs at least 100X that of the
susceptible cells. Resistance also engenders a 5% fitness cost which
is manifest as a 5% lower maximal growth rate of bacteria in those
states. This assumed cost is in the range of what has been observed
for M. marinum mutants resistant to the antibiotics considered in
this study (unpublished results). We allow migration at rates fls
(from latent to susceptible) and fsl (from susceptible to latent) cells
per hour, representing either a physical or a physiological
translocation between the compartments.
Resources for bacterial growth enter and are removed from the
habitat (host) at a constant rate, w ml per hour. The bacteria,
however, are removed from the habitat at two rates, w for S0, S1,
S2 and S12, and wL for L0, L1, L2, and L12, where w. wL. For
the pharmacodynamic functions, we use the two-drug Hill
functions with the biphasic model for the interaction coefficient
described above. For pharmacokinetics we assume that a fixed
dose A1max and A2max of each drug is added every T hours. In
addition to washout at rate w, both drugs also decay at a rate d
mg/L per hour. In these simulations we assume that at the onset of
treatment, the sensitive population is initially at a density of
S0=5610
7 in the main compartment [41] and L0=5610
4 cells
per ml in the refractory compartment.
As would be anticipated for hosts infected with numbers of
bacteria that exceed the reciprocal of the mutation rates, we
assume that there are minority populations of bacteria resistant to
single antibiotics, S1, S2, L1 and L2, with a relative frequency of
10
23 to the corresponding susceptible population [42]. We also
allow resistance to single drugs to evolve during the course of the
simulations at rates proportional to the product of the number of
individuals of each ancestral state and a mutation rate. The actual
generation of mutants occurs in a semi-stochastic manner, via a
Monte Carlo routine. At each time step (Dt) in the finite step size
(Euler) simulation, the probability that a mutant would be
generated is the product of the number of individuals of the
genotype, Dt and the mutation rate m. When the random number
is less than this product, a mutant is added to the noted
population, e.g. when S1 is generated from S0, a bacterium is
added to the S1 state and one removed from the S0 state. We use
step sizes of Dt so that the probability of a mutant being added at a
particular time interval is always less than 1. For these simulations,
m takes values in the range of that estimated from fluctuation
experiments for different antibiotics and M. marinum (unpublished
results). There are no doubly resistant cells, S12 and L12 at the
start of the simulations, but they can evolve by mutation from the
single resistant states.
In Figure 5, we follow the changes in density of the different
bacterial populations in the main compartment (5a) and in the
refractory compartment (5b). The PD parameter values used in
this simulation are those in the range estimated in our experiments
for the combination of rifampin (A1) and amikacin (A2). These
Figure 2. Predicted and observed growth/death rates of M. marinum exposed to different combinations of two antibiotics. Curves
without markers represent predicted theoretical rates, and curves with markers represent observed experimental rates. Values of a represent different
degrees of interaction between antibiotics. Positive values indicate synergy, negative values antagonism, and values of zero, additivity. (a) amikacin +
clarithromycin (b) amikacin + moxifloxacin (c) amikacin + streptomycin (d) clarithromycin + moxifloxacin (e) clarithromycin + streptomycin (f) rifampin
+ amikacin (g) rifampin + clarithromycin (h) rifampin + moxifloxacin (i) rifampin + streptomycin (j) streptomycin + moxifloxacin.
doi:10.1371/journal.ppat.1002487.g002
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their respective MICs and decline in concentration due to flow
and a decay rate, d=0.075 per hour. With these parameters, the
overall densities of the sensitive and single-resistant populations
continue to decline during the course of the simulation. In the
main compartment this decline is punctuated by oscillations in
density reflecting the waxing and waning of the antibiotic
concentration, with net decline each hour. The single resistant
populations are cleared earlier than the sensitive for two reasons:
their lower initial densities and their lower fitness relative to the
sensitive bacteria. This interpretation was confirmed by running
simulations in which single resistant populations were at higher
initial densities and had lower fitness costs (data not shown). Under
these conditions, their resistance to single antibiotics does not
make up for this fitness cost.
In the refractory compartment, the rate of change in cell density
is lower and the oscillations are not manifest to the same extent as
in the main compartment. This occurs because the replication and
washout rates are lower, as is the rate of kill by the antibiotics. As a
result of continuous migration of cells from and to the slower-
growing population, the rate of decline in the density of cells in the
main compartment is reduced whilst that in the refractory
compartment increased relative to what would obtain were they
the sole compartments or not connected. Said another way, the
existence of a refractory compartment prolongs the term of
therapy.
To compare the relative efficacy of different combinations of
antibiotics, we ran these simulations with the estimated PD
parameter values obtained for the different combinations of drugs.
In addition to simulations with symmetric antibiotic concentra-
tions for the two drugs, we also conducted these simulation
experiments with asymmetric antibiotic concentrations. The
former were initiated with 5xMIC of both drugs and the latter
with 5xMIC of one antibiotic and 2xMIC of the other. As a result
of flow and decay, the asymmetric drug concentration simulations
include periods where both drugs are above the MIC, one above
and one below, and both below. The interaction coefficients used
in these simulations are those estimated from the corresponding
symmetric and asymmetric concentration experiments. As our
measure of the efficacy of treatment, we considered the time until
the total density of bacteria was less than one (time to clearance).
The results of these simulations are presented in Table 2. While in
some runs doubly resistant mutants emerged, ascended and
thereby precluded clearance, these were not included in the
Table 2 clearance data. The frequencies of runs in which double
resistance emerged are considered separately.
Although mutation is a stochastic process, there was effectively
no between-run variation in the time before clearance. For eight
out of the ten combinations, clearance occurred in less than
1600 hours. The rifampin + amikacin combination was the most
effective, leading to clearance in 1080 hrs. The combinations of
clarithromycin + moxifloxacin and clarithromycin + streptomycin
Figure 3. The interaction parameter as a function of antibiotic concentration. Independent linear regressions are shown for sub-MIC
(triangles) and supra-MIC (circles) concentrations. (a) amikacin + clarithromycin (b) amikacin + moxifloxacin (c) amikacin + streptomycin (d)
clarithromycin + moxifloxacin (e) clarithromycin + streptomycin (f) rifampin + amikacin (g) rifampin + clarithromycin (h) rifampin + moxifloxacin (i)
rifampin + streptomycin (j) streptomycin + moxifloxacin.
doi:10.1371/journal.ppat.1002487.g003
Figure 4. Two-compartment population and evolutionary dynamic model of two-drug antibiotic therapy. Main (active) compartment:
S0, bacteria susceptible to both antibiotics; S1, bacteria resistant to antibiotic 1; S2, bacteria resistant to antibiotic 2, S12, bacteria resistant to both
antibiotics. Latent (refractory) compartment: L0, bacteria susceptible to both antibiotics; L1, bacteria resistant to antibiotic 1; L2, bacteria resistant to
antibiotic 2, L12, bacteria resistant to both antibiotics. C, reservoir resource concentration; R, internal concentration of the limiting resource; A1 and
A2, internal concentrations of the antibiotics; A1max and A2max, concentration of antibiotics added periodically; w, flow rate of resources into and
out of the compartments; wL, flow rate of latent population from the latent compartment.
doi:10.1371/journal.ppat.1002487.g004
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PLoS Pathogens | www.plospathogens.org 7 January 2012 | Volume 8 | Issue 1 | e1002487Figure 5. Clearance dynamics for different subpopulations in the main and refractory compartments of the PD/PK model. Parameters
used are those observed for the rifampin (A1) + amikacin (A2) combination. In these simulations, w and wL are, respectively, 0.02 and 0.002 per hour;
fls=f sl=0.001; the antibiotic decay rate is d=0.075 hr
21 and the maximum and minimum bacterial growth rate for each subpopulation in the latent
compartment is 10% of those in the active. (a) Main compartment, (b) Refractory compartment.
doi:10.1371/journal.ppat.1002487.g005
Table 2. Relative efficacy of antibiotic combinations in clearing bacteria during simulated infections.
Time to clearance (hours)
Antibiotic combination Antibiotics at symmetric xMIC concentrations
Antibiotics at asymmetric xMIC
concentrations
Rifampin + Amikacin 1080 2785
Rifampin + Clarithromycin 1527 2521
Rifampin + Streptomycin 1433 2396
Rifampin + Moxifloxacin 1453 2642
Amikacin + Clarithromycin 1428 2568
Amikacin + Streptomycin 1315 2452
Amikacin + Moxifloxacin 1090 2690
Clarithromycin + Streptomycin 11668 13035
Clarithromycin + Moxifloxacin 4530 5793
Streptomycin + Moxifloxacin 1422 2257
doi:10.1371/journal.ppat.1002487.t002
Two-Drug Pharmacodynamics of Mycobacterial Chemotherapy
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rifampin + amikacin combination, the clarithromycin + moxi-
floxacin combination took some 4 times longer, with the
clarithromycin + streptomycin combination taking approximately
11 times longer. This is what would be anticipated from the
relative pharmacodynamics of the different drug combinations
(Figure 2).
As in the symmetric case, the majority of the antibiotic
combinations in the asymmetric simulations cleared the infection
over a relatively similar period, i.e. ,2800 hours. The reason that
the average time to clearance is greater for the asymmetric
concentrations is because there is a lower peak concentration for
one of the two drugs, rather than equal peaks. While clarithro-
mycin + streptomycin and clarithromycin + moxifloxacin
remained the least effective drugs, the most effective combination
was streptomycin + moxifloxacin rather than rifampin + amikacin.
Compared to streptomycin + moxifloxacin, clarithromycin +
moxifloxacin and clarithromycin + streptomycin took, respective-
ly, approximately 2.5 and 6 times longer to clear the infection.
The evolution of multiple resistance
What is the relationship between the PD of the antibiotics and
the likelihood of mutants resistant to both drugs emerging? To
address this question, we separately performed 1000 simulation
experiments using three sets of parameters reflecting the ‘extreme’
conditions of relative efficacy for the symmetric combinations:
rifampin + amikacin, clarithromycin + moxifloxacin and clarith-
romycin + streptomycin. The aggregate results from these
simulation experiments are presented in column one of Table 3.
As can be seen, the two-drug resistant population emerged in
only a few runs. Although the relative number of runs in which
resistance emerged for the different drug combinations is what
would be anticipated from the clearance data in Table 2, the
differences were not statistically significant (p,0.525). With these
parameters, the frequency of two-drug resistance emerging was
low and was roughly the same for all three pairs of drugs.
Non-adherence
In a number of epidemiological studies, non-adherence to the
prescribed treatment regime has been associated with adverse
therapeutic outcomes [43], longer terms of treatment and acquired
drug resistance [44,45]. In practice, non-adherence takes a
number of forms and depends on a variety of factors such as
organization of treatment and care (access to services, length,
drug-type and other requirements for therapy, support services,
etc) individual interpretations of illness and wellness, drug side
effects and the social context in which therapy is undertaken [46].
How does non-adherence contribute to the amount of time
required for microbiological cure and the likelihood of multi-drug
resistance emerging within a host during the course of treatment?
How sensitive are different drug combinations to the adverse
outcomes of non-adherence? To address these questions, we
considered three broadly-inclusive types of non-adherence that we
call random, thermostat [39], and drug holiday (described below).
To explore the relationship between the PD of the drug
combinations and the frequency of non-adherence with respect
to the generation of the double resistant mutants, we conducted
1000 runs for each of the three aforementioned drug combinations
and the different non-adherence scenarios. The results of these
simulations are presented in Table 3.
Random non-adherence
We model this scenario in the following manner: At each dosing
period there is a probability P (0#P#1) that both drugs will be
taken and a corresponding probability (1-P) that neither will be
taken. To simulate this we use a Monte Carlo routine where if the
random number, r#P, the drugs are administered, but if r.P that
dosing period is skipped. In Figure 6(a), we illustrate this process
for a single run where two-drug resistance emerges. Non-
adherence is reflected in a hiatus in the dosing and a rise in the
density of all the bacterial populations. There are periods, such as
between 600 and 648 hours, where consecutive doses are missed.
This results in a substantial rise in the density of bacteria and
thereby an increase in the likelihood of a doubly resistant mutant
being generated.
With 10% random non-adherence (P=0.9), there was no
significant difference among drug combinations in the probability
of resistance arising (p,0.073) (Table 3, Column 2). With 20%
random non-adherence (P=0.8) there was a highly significant
drug combination effect, p,0.001 (Table 3, Column 3). The
likelihood of multiple resistance arising with 20% non-adherence
was negatively related to the microbiological efficacy of these
different drug combinations. The relationship between the
probability of a doubly resistant population emerging for different
levels of random non-adherence was also directly related to the
microbiological efficacy of the drug combinations. For the
rifampin + amikacin combination, there was no significant
difference among the 0, 10% and 20% non-adherence regimes
(p,0.435). For the other two pairs, there were significant p,0.001
relationships between the frequency of non-adherence and the
likelihood of double resistance emerging.
Thermostat non-adherence
We simulate this by incorporating a situation in which
treatment ceases when the density of the rapidly growing
population falls below 10
4 and doesn’t commence again until
the density exceeds 10
6. The situation we are mimicking is one in
which patients cease taking their antibiotics when they are feeling
better (the bacterial densities are low enough not to be
symptomatic) and do not take the drugs again until the density
Table 3. Percent of 1000 runs in which multi-drug resistant mutants emerged by 1000 hours.
Random non-adherence
Antibiotic combination
Complete
adherence
10% non-
adherence
20% non-
adherence
Thermostat non-
adherence
Extended drug
holiday non-
adherence
Rifampin + Amikacin 0.8 1.2 1.4 100 1.7
Clarithromycin + Moxifloxacin 1.2 2.1 3.9 1.3 5.2
Clarithromycin + Streptomycin 1.3 2.6 4.1 1.7 5.8
doi:10.1371/journal.ppat.1002487.t003
Two-Drug Pharmacodynamics of Mycobacterial Chemotherapy
PLoS Pathogens | www.plospathogens.org 9 January 2012 | Volume 8 | Issue 1 | e1002487is high enough to be symptomatic. We illustrate this situation in
Figure 6(b) with a run in which two-drug resistance emerged.
In column 4 of Table 3, we summarize the results of 1000
simulations of thermostat non-adherence for the three drug
combinations. With respect to our measure of microbiological
efficacy, the thermostat non-adherence scenario seems paradox-
ical. Two-drug resistance emerged far more frequently in the runs
with the most microbiologically effective drug combination, indeed
in all 1000 runs. The reason for this is that the more effective drug
combination reduced the density more rapidly than the less
effective drug combinations. As a result there were far more
frequent periods where drugs were not taken and the single-
resistant populations ascended to high-enough densities where
two-drug resistant mutants were produced with a very high
probability. Under the parameter conditions of this simulation, the
non-adherence threshold was never crossed in any of the 1000
simulations for either of the two less effective drugs.
Drug holidays
We model this scenario in the following manner: Both drugs are
taken for 4 consecutive dosing periods, at which time neither drug
is taken for the subsequent 3 dosing periods. This regime continues
throughout the duration of simulated treatment. We are
mimicking a situation where holidays are imposed because the
drugs may be costly, limited in their availability or induce
debilitating side effects that are alleviated by terminating treatment
for an interval. In Figure 6(c) we illustrate this situation for a run
where two-drug resistance emerged. As noted in the last column of
Table 3, the overall frequency of double resistance was on the
order of 5% and similar for the two microbiologically less effective
drug combinations. For the most effective drug combination,
relative to complete adherence, the drug holidays doubled the
likelihood of two-drug resistance emerging.
Discussion
With few exceptions, studies of the pharmacodynamics (PD) of
antibiotics and bacteria have been restricted to single drugs
[10219]. Some infections, particularly those that are long-term
like tuberculosis, require multiple antibiotics for treatment to be
effective. It follows then, that for the rational design of treatment
protocols for these infections, multidrug PD analyses are necessary.
Our results indicate that Hill functions provide an excellent fit
for the single-drug PD for Mycobacteria marinum and each of the five
Figure 6. Dynamics of non-adherence with therapy. Changes in the absolute concentrations of the antibiotics and densities of bacteria: S0-
sensitive to both drugs, S1- resistant to drug A1, S2- resistant to drug A2, and S12- resistant to both A1 and A2. (a) Random non-adherence:
Parameters used are those estimated for clarithromycin + streptomycin, assuming a 20% probability of non-adherence at each dosing. (b) Thermostat
non-adherence: Parameters used are those estimated for rifampin + amikacin. (c) Drug holiday non-adherence: Parameters used are those estimated
for clarithromycin + moxifloxacin. These figures represent runs in which double resistance (S12) emerged. The relative frequencies of this outcome
are shown in Table 3. See the text for descriptions of these different modes of non-adherence.
doi:10.1371/journal.ppat.1002487.g006
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moxifloxacin, rifampin and streptomycin. On the other hand, if, as
is assumed in the classical model of Greco and colleagues [25,26],
the interactions between drugs is expressed as a single parameter
with a constant value, two-drug Hill function models do not fit the
PD observed for any of the 10 pairs of drugs considered. In all
cases, at lower antibiotic concentrations the interactions between
the drugs is antagonistic; they are less effective together than
anticipated from their action alone. As the antibiotic concentra-
tions increase, this drug-drug interaction becomes relatively more
synergistic and approaches constancy. To address this phenom-
enon, we allow for two phases of the drug-drug interaction, one for
low (sub-MIC) and one for high (supra-MIC) concentrations with
an antibiotic concentration-dependent function for the interaction
term. Albeit not as convenient as a unique parameter, these
functions can be readily estimated from time-kill data. Most
importantly, the biphasic drug interaction Hill function models
thus generated provide quantitatively accurate analogues of the
PDs of all 10 pairs of antibiotics examined.
It has been hypothesized that there are subpopulations of
bacteria within an infected TB host that exhibit differential growth
rates and, by extension, variable susceptibility to antimycobacterial
agents [38,47250]. Here, we develop a simple mathematical
model that accounts for this within-host bacterial heterogeneity by
assuming that there are two ‘compartments’, one that houses
rapidly-growing and the other slowly-growing bacteria. The model
incorporates the possibility of non-adherence to therapy, which is
considered to be one of the major contributory factors to TB
treatment failure [43,45,51].
Our computer simulations of tuberculosis chemotherapy
employing the empirically estimated biphasic Hill functions
suggest that there can be substantial differences among drug
combinations in treatment efficacy, as measured by the time to
clearance. Of the ten antibiotic pairs we consider, rifampin +
amikacin is the most effective and streptomycin + clarithromycin
the least, with some eleven-fold difference in the time before
clearance. With the parameters used in our semi-stochastic model
of treatment and assuming different probabilities for the
occurrence of random non-adherence, either complete adherence
or limited non-adherence to the therapeutic regime would not be
manifest as a significant difference among drug combinations in
the likelihood of the generation and ascent of two-drug resistant
mutants. However, with greater rates of non-adherence, the
likelihood of two-drug resistance emerging becomes increasingly
dependent on the drug combination employed. The emergence of
two-drug resistance due to random non-adherence is more likely
for less microbiologically effective drug combinations than those
that are more effective.
With externally imposed regular drug holidays, the likelihood of
emergence of two-drug resistance is also inversely proportional to
the microbiological efficacy of the antibiotic combination. Our
results suggest that quite a different situation obtains when the
drug holidays depend on the bacterial load, as is the case for
thermostat non-adherence. Under the parameter conditions used
in our simulations, the most microbiologically effective drug
combination almost invariably leads to the emergence of two-drug
resistance. As a result of the enhanced efficacy, the time required
to reduce the bacterial densities to below a non-symptomatic
threshold is decreased for the more effective antibiotic combina-
tion. Consequently, in the course of therapy this threshold and the
resulting drug holidays are reached and manifest more frequently
for the more effective drug combinations than the less effective.
During these holidays, intermediates resistant to single antibiotics
can reach high enough densities for the single drug resistant clones
to acquire the second mutation needed for two-drug resistance. It
is easy to write-off this paradoxical result as an artifact of the
model because of the extraordinary frequency of two-drug
resistance emerging in our simulations. On the other hand, this
outcome is not entirely unreasonable if indeed patients go off
treatment when they are no longer symptomatic but remain
infected. While we are not championing the validity of this
potential downside of effective chemotherapy, we believe it may
warrant further consideration.
This jointly theoretical and experimental study raises important
as well as intriguing issues about the interactions between
antibiotics of different classes and how these interactions are
affected by their concentrations. Our results, however, provide no
information about the physiological, molecular and other
processes underlying these interactions. What are these processes?
It is clear that answering this question is not going to be trivial. As
Yeh and Kishony argue, intuitive deductions about the type of
interactions between drugs based on the metabolic pathways of
action of their individual action are, at best, simplifications [52].
Antibiotic action is pleiotropic and not limited to structural or
metabolic alterations to a particular target. As such, the resulting
cellular death or growth cessation upon antibiotic use can be due
to multiple factors. Although there is evidence that antibiotics of
different types kill by a common non-specific mechanism, the
production of hydroxyl radicals [53255], the rates of kill vary
among drugs and their concentrations in ways that cannot be
predicted from their respective targets and mode of action.
Particularly intriguing is the antagonistic interaction observed at
lower (sub-MIC) concentrations among all the antibiotic pairs
studied. Why? How? We know that antibiotics at both sub- and
supra-MIC concentrations affect mycobacterial transcription
patterns in a variety of ways and can lead to a number of
physiological and biochemical stress responses [56,57]. Some of
these responses have been observed to reduce antimicrobial
activity through actions such as antibiotic efflux, ribosomal
protection, etc [58261]. One possible explanation is that at sub-
MIC concentrations for two drugs, these stress responses make the
bacteria more refractory to antibiotic activity, but the drugs do not
generate enough cidal activity to overcome this refractoriness – a
phenomenon that would manifest as pharmacodynamic antago-
nism.
To paraphrase the statistician George Box, ‘All models (and
model systems) are wrong, some are useful’ [62]. We endorse this
perspective and of course believe our model and model system are
useful. However, we see this utility restricted to its potential to
evaluate, in vitro, the efficacy of different antibiotic combinations
for clinical applications. Our models are not intended to be
quantitatively exact analogs of tuberculosis chemotherapy but
rather to generate a framework within which questions relevant to
TB treatment could be approached. They were designed in the
tradition advocated by Richard Levins [63], to maximize reality
and generality at the loss of precision. Thus, even though the
pharmacodynamic parameters are directly estimated and drug
doses simulated in clinically realistic range [64], the time scale in
these simulations do not reflect the actual time course of
tuberculosis chemotherapy and dosing schedule.
We elected to do the experimental work on this project with M.
marinum because we are particularly interested in multi-drug
treatment of tuberculosis. As a model for Mtb, M. marinum has its
virtues and limitations. In addition to being more convenient to
work with than Mtb, M. marinum infections in fish and amphibians
demonstrate key elements of Mtb infections in humans [34,35]. Of
particular import is the formation of epitheloid granulomas with
lymphocytic involvement [65]. Thus, using either fish or
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predictions of our models. M. marinum is also limited as a model
for multi-drug treatment of Mtb primarily because of its natural
resistance (relatively high MICs) to some the first line antibiotics
used to treat tuberculosis, in particular isoniazid, ethambutol and
pyrazinamide. While one of the antibiotics used in this study,
rifampin, is a first line tuberculosis drug, the others are only used
in cases where first line drugs fail.
Albeit simple, our TB chemotherapy model incorporates some,
but clearly not all of the complexity of a M. tuberculosis infections
and their treatment. It accounts for the subpopulation heteroge-
neity that has been postulated for these infections [38,47250] and
the effects of that heterogeneity on the PD of the antibiotic
treatment. On the other hand, this model does not formally
account for the third subpopulation suggested by the recent
observation that some Mycobacteria in macrophages induce efflux
pumps that make them tolerant to antibiotics [66]. At a
pharmacodynamic level, this phenomenon is, however, somewhat
subsumed in our model by the presence of a subpopulation of
bacteria that is less susceptible to the antibiotics than another
segment of the population. Additionally, while our model takes
into account three forms of the non-adherence that is considered
to be one of the major contributory factors to TB treatment failure
[43,45,51], it certainly does not incorporate all of the nuances of
non-adherence.
We are unaware of other studies that have combined
experimental work on the PD of multiple drugs with a quantitative
consideration of the potential clinical implications of these PDs.
There have been investigations of the PD of multiple antibiotics
that have employed a fitting approach for a quantitative
description of the interactions between drugs [32,67]. Similar to
that observed here, some of these studies provide evidence that the
interactions between antibiotics can vary with their concentrations
[22,32,68]. Nevertheless, to our knowledge, this quantitative
relationship has not been taken into account in the design of
treatment programs; the interactions between different antibiotics
are simply described as additive, synergistic or antagonistic, but
without consideration of how this relationship changes with
antibiotic concentration. The models we develop and the
experimental methods we employ in this study can be used for
any combinations of bactericidal antibiotics and bacteria that can
be grown in vitro. Whether the biphasic interaction phenomenon
observed with M. marinum and the five drugs considered would be
manifest with other bacteria and drug combinations remains to be
seen.
Materials and Methods
Bacteria and media
Mycobacterium marinum strain ATCC BAA-535/M was used in all
experiments. Bacteria were grown in Middlebrook 7H9 broth
(Difco, Detroit, Mich.) supplemented with 0.2% glycerol and 10%
albumin-dextrose complex (7H9) at 32uC. Cell densities were
estimated by plating on Middlebrook 7H10 agar (Difco)
supplemented with 0.5% glycerol and 10% oleic acid-albumin-
dextrose complex (7H10) at 32uC.
Antibiotics
Rifampin, amikacin, clarithromycin, streptomycin (Sigma, St.
Louis, MO, USA) and moxifloxacin (Bayer, Pittsburgh, PA, USA)
were purchased commercially. Stock solutions were prepared by
dissolving the antibiotics in sterile water or methanol, and
appropriate dilutions were made in 7H9 broth immediately before
use.
Time-kill experiments for generating single-antibiotic Hill
functions
Mid-log cultures of M. marinum were diluted in fresh medium to
obtain a density of approximately 5610
6 CFU/mL. 200 mL
aliquots of this culture were introduced into wells in a 12-well plate
containing 1.8 mL of antibiotic solution. The plates were
incubated with shaking at 32uC for 72 h, and samples were taken
every 12 h to determine viable CFU’s.
MIC determination
Minimum Inhibitory Concentrations (MICs) were estimated
using a broth microdilution procedure similar to that recom-
mended by the CLSI[37] (7H9 was used instead of Mueller-
Hinton Broth). Initial inoculating bacterial densities were similar
to the densities used to initiate time-kill experiments in order to
account for the inoculum effect on MIC demonstrated in Udekwu
et al. [69].
Antibiotic-kill experiments for generating two-drug PD
functions
Antibiotics were combined to generate solutions that contained
0.1, 0.5, 1.0, 2.0, 5.0 and 10.0 multiples of MIC (xMIC) of each
antibiotic. Mid-log cultures of M. marinum were diluted in fresh
medium to obtain a density of approximately 5610
6 CFU/mL.
200 mL aliquots of this culture were introduced into wells in a 12-
well plate containing 1.8 mL of antibiotic solution. The plates
were incubated with shaking at 32uC for 72 h, and samples were
taken at the end of the incubation. The experiment was repeated
four times, and gave good quantitative and qualitative replication.
We show a representative experiment in the Results section of the
manuscript.
Drug interaction modeling
As in Regoes et al., [70] we assume that for single antibiotics,
bacterial net growth in the presence of an antibiotic, y(A), is
dependent on the growth rate of the bacteria in the absence of
antibiotics, y max, and the death rate due to the antibiotic. The
latter is a Hill function, G, composed of the following parameters:
y max; y min, the maximum antibiotic-generated bacterial killing;
zMIC, the pharmacodynamic MIC; and k, which describes the
sigmoidicity of the Hill function [70]. i.e.:
y(Ai)~ymax{Hi(Ai) ð1Þ
Where
Hi(Ai)~
(ymax{ymin(i))  
Ai
zMIC
  
Ai
zMIC
   k
{
ymin(i)
ymax
  
k 2
6 6 6 4
3
7 7 7 5
ð2Þ
Bacterial net growth rates were determined from the change in
bacterial density over the time-kill period, and the pharmacody-
namic function was fit to these data using the least square
algorithm nls() of R (www.r-project.org) to obtain estimates for the
parameters of the Hill function. For two-antibiotic combinations,
we incorporated an interaction parameter (a) into the Hill-
function mediated killing by both antibiotics. Thus, net bacterial
growth rates would be described by the following equation:
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and the rate of change in the viable cell density of bacteria, D,
treated with combinations of two drugs given by,
dD
dt
~y(Ai,Aj)   D ð4Þ
Estimation of drug interaction parameter (a)
By assessing bacterial killing over 72 h when exponentially-
growing cultures were challenged with pairwise combinations of
antibiotics (Ai and Aj) at different concentrations, we obtained
empirical estimates for net bacterial growth rates in the presence of
both antibiotics, y exp. As the theoretical analyses outlined above
generate estimates for ymax,H i(Ai) and Hj(Aj), algebraically
rearranging the net bacterial growth rate equation gives an
equation for determining a:
a~
yexp{(ymax{H(Ai){H(Aj))
H(Ai)   H(Aj)
ð5Þ
Numerical solutions
To follow the predicted change in the viable cell density of
bacteria, we use numerical solutions to the differential equation (4)
programmed in Berkeley Madonna
TM. Copies of this program
and other programs used in this study and instructions for their use
can be obtained on www.eclf.net/programs.
Supporting Information
Figure S1 Predicted and observed growth rates of M.
marinum exposed to asymmetric sub-MIC antibiotic
concentrations. Blue bars represent predicted rates anticipated
from the Hill functions under the assumption that the drugs are
acting additively. Red bars represent the growth rates observed for
the noted concentrations. Multiples-of-MIC concentrations at
which antibiotics are combined are indicated. R-rifampin; A-
amikacin; C-clarithromycin; S-streptomycin; M-moxifloxacin. (a)
amikacin + clarithromycin (b) amikacin + moxifloxacin (c)
amikacin + streptomycin (d) clarithromycin + moxifloxacin (e)
clarithromycin + streptomycin (f) rifampin + amikacin (g) rifampin
+ clarithromycin (h) rifampin + moxifloxacin (i) rifampin +
streptomycin (j) streptomycin + moxifloxacin.
(TIF)
Figure S2 Predicted and observed growth/death rates
of M. marinum exposed to sub- and supra-MIC
antibiotic combinations. Growth/death rates observed for
single drugs in comparison to that observed with those drugs in
combination with a sub-MIC concentration of second antibiotic.
Red bars represent combinations of antibiotics at 2xMIC and
0.1xMIC; blue bars represent combinations of antibiotics at
5xMIC and 0.5xMIC. For amikacin, only the lower
(2xMIC+0.1xMIC) concentration results are presented. At the
higher concentrations the extent of kill exceeded the limit of
detection. R-rifampin; A-amikacin; C-clarithromycin; S-strepto-
mycin; M-moxifloxacin. (a) rifampin (b) amikacin (c) clarithromy-
cin (d) streptomycin (e) moxifloxacin.
(TIF)
Figure S3 Predicted and observed death rates of M.
marinum exposed to asymmetric supra-MIC antibiotic
concentrations. Blue bars represent predicted rates anticipated
from the Hill functions under the assumption that the drugs are
acting additively. Red bars represent the growth rates observed for
the noted concentrations. Multiples-of-MIC concentrations at
which antibiotics are combined are indicated. R-rifampin; A-
amikacin; C-clarithromycin; S-streptomycin; M-moxifloxacin. (a)
amikacin + clarithromycin (b) amikacin + moxifloxacin (c)
amikacin + streptomycin (d) clarithromycin + moxifloxacin (e)
clarithromycin + streptomycin (f) rifampin + amikacin (g) rifampin
+ clarithromycin (h) rifampin + moxifloxacin (i) rifampin +
streptomycin (j) streptomycin + moxifloxacin.
(TIF)
Table S1 Linear regression parameters for the biphasic
antibiotic interaction function.
(DOC)
Table S2 Value of interaction parameter at different
combinations of sub-MIC concentrations.
(DOC)
Protocol S1 Differential equations used for simulation
of the mathematical model.
(DOC)
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